Clinigen Group (LON:CLIN) Upgraded to “Buy” at Liberum Capital
Liberum Capital upgraded shares of Clinigen Group (LON:CLIN) to a buy rating in a research note released on Wednesday morning, ThisIsMoney.Co.Uk reports.
Several other equities research analysts have also recently issued reports on CLIN. Peel Hunt restated a buy rating on shares of Clinigen Group in a research report on Thursday, March 5th. Royal Bank of Canada restated a top pick rating on shares of Clinigen Group in a research report on Tuesday, March 3rd.
Shares of LON:CLIN traded up GBX 117.20 ($1.54) during midday trading on Wednesday, hitting GBX 475 ($6.25). The company’s stock had a trading volume of 3,195,438 shares, compared to its average volume of 432,646. Clinigen Group has a 12-month low of GBX 600.50 ($7.90) and a 12-month high of GBX 1,069 ($14.06). The company has a market cap of $631.03 million and a P/E ratio of 45.67. The business’s 50 day simple moving average is GBX 785.92 and its 200 day simple moving average is GBX 859.93. The company has a debt-to-equity ratio of 82.15, a quick ratio of 0.86 and a current ratio of 1.12.
The company also recently disclosed a dividend, which will be paid on Friday, April 17th. Investors of record on Thursday, March 19th will be given a dividend of GBX 2.15 ($0.03) per share. This represents a yield of 0.29%. The ex-dividend date is Thursday, March 19th. Clinigen Group’s payout ratio is currently 0.67%.
About Clinigen Group
Clinigen Group plc operates as a specialty pharmaceutical and services company. The company operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines in the Africa and Asia Pacific region.
Featured Story: Purposes and Functions of the Federal Reserve
Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.